Table 3.

Cupic study evaluation of the risk/benefit of the treatment cirrhotic patients with telaprevir or boceprevir triple therapy considering the chances of death or severe complications and sustained virologic response 12 according to cutoffs of serum albumin level and platelet count n (%)

Factors	Platelet count	Platelet count
	> 100000/mm3	≤ 100000/mm3
Serum albumin level > 35 g/L
Patients with severe complications or death)	19 (6.2)	9 (12.2)
SVR12	168 (54.9)	27 (36.5)
Serum albumin level > 35 g/L
Patients with severe complications or death	5 (16.1)	19 (51.4)
SVR12	9 (29.0)	10 (27.0)

Adapted from Hézode et al[50]. SVR12: Sustained virologic response at 12 wk after ending of treatment.